RxDoctor Payments Data

Katie Gee, NP

Adult Health · Thomasville, GANPI 1447750435

Payments from drug & device makers

$4,105in general payments, 2019–2025

Across 221 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$685
  • Novartis$567
  • Abiomed$361
  • Amgen$316
  • E.r. Squibb & Sons, L.L.C.$291
  • Pfizer$260
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,105 in reported general payments places this provider in the 85th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$12,951
Medicare patients
96
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan31$19,061
FarxigaDapagliflozin Propanediol29$18,371
EliquisApixaban21$12,489
JardianceEmpagliflozin19$11,228
XareltoRivaroxaban14$10,733
BrilintaTicagrelor17$7,342
Ranolazine ErRanolazine25$1,096
Metoprolol Succinate84$834
ClopidogrelClopidogrel Bisulfate37$350
Carvedilol36$290
Losartan Potassium41$278
Atorvastatin Calcium22$265
Isosorbide Mononitrate ErIsosorbide Mononitrate23$149
Spironolactone23$111
Ezetimibe14$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$174$25,71346 claims
NovartisEntresto$567$19,06131 claims
PfizerEliquis$260$12,48921 claims
Boehringer IngelheimJardiance$171$11,22819 claims
Johnson & JohnsonXarelto$685$10,73314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 577 adult health providers in Georgia.

Other adult health in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →